Neurofilament light chain (NfL) has been identified as reliable fluid biomarker for neuroaxonal damage in neurodegenerative diseases [17], with first studies showing higher NfL levels in MSA compared to PD [18, 19]. This evidence concerns the gene NEFL and Parkinson disease.